A combination therapy is disclosed for the treatment of a patient, such as a human, with a monoclonal antibody. The methods can include administering to a patient a monoclonal antibody, for example, a TNT-alpha inhibitor such as adalimumab, certolizumab pegol, golimumab, and infliximab and administering to the patient colchicine. The present teachings also provide a therapeutic combination and a kit including the therapeutic combination.